← All indications
Aortic Valve Stenosis
A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA.
Subtype terms (2)
More specific conditions that are subtypes of Aortic Valve Stenosis in the MeSH hierarchy.
- Aortic Stenosis, Subvalvular
19 drugs (15 approved, 4 experimental)
- Aortic Stenosis, Supravalvular
Drugs by status
Phase 4 trials (32)
- edoxaban
- methylprednisolone
- dabigatran
- candesartan
- captopril
- chlorthalidone
- tadalafil
- fluvastatin
- empagliflozin
- ferric carboxymaltose
- l-glutamine
- amlodipine
- warfarin
- iron dextran
- levosimendan
- atorvastatin
- ticagrelor
- acetylsalicylic acid
- sufentanil
- desflurane
- trandolapril
- losartan
- rivaroxaban
- sildenafil
- clopidogrel
- dapagliflozin
- antithrombin iii (human)
- sodium chloride
- bisoprolol
- protamine sulfate
- +2 more
Phase 3 trials (12)
Phase 2 trials (10)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (40)
- Daiichi Sankyo
- Merck
- Pfizer
- AORTICA Group
- Baxalta
- Vifor Inc.
- CardioVascular Research Foundation, Korea
- China International Medical Foundation
- Aarhus University
- Keio University
- Korea University
- Medical University of Warsaw
- Pontificia Universidad Catolica de Chile
- Seoul National University
- Spanish Society of Cardiology
- University of Rochester
- University of Southern Denmark
- University of Bari
- Yonsei University
- Aalborg University
- Universidad de la Republica
- University of Copenhagen
- University of Turku
- University of Ulsan
- University of Vienna
- Hospital de Meixoeiro
- Boryung Pharmaceutical Company
- Hanmi Pharmaceutical
- University of Montpellier
- St. Antonius Hospital, Nieuwegein
- +10 more
Organization Involved with Phase 3 Indications (25)
- The Medicines Company
- Bristol-Myers Squibb
- AstraZeneca
- Bayer
- ECRI bv
- Duke University
- Hospital Universitari Son Dureta
- RWTH Aachen University
- University of Ottawa
- University of Athens
- University of Bonn
- University of Bordeaux
- Laval University
- Icahn School of Medicine at Mount Sinai
- University of Limoges
- University of Strasbourg
- Cha Medical University
- University of Paris
- Humboldt University
- Erasmus University Rotterdam
- Cardialysis BV
- Action Research Group
- BIOMED
- University of Helsinki
- CryoLife
Organization Involved with Phase 2 Indications (12)
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (8)